Chronic Dis Transl Med 2019 Mar 19;5(1):15-24. Epub 2019 Mar 19.
Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA 17822, USA.
Hodgkin's lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin's lymphoma. This is a review of the current advances in the management of Hodgkin's lymphoma and a review of ongoing clinical trials in the field.